Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection (RIFAVIRENZ)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT01986543
First received: November 12, 2013
Last updated: October 4, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)